Bone conduction hearing implants (BCHIs); life-changing surgery. A quality of life (QoL) study reporting the impact of BCHI surgery on 163 patients' well-being.

This study aimed to determine improvement in health-related quality of life (HRQoL) using a validated disease-specific patient-reported outcome measure (PROM) questionnaire in patients undergoing bone-conduction hearing implant (BCHI) insertion. A mixed retrospective and prospective correlational study. Single tertiary referral center in the United Kingdom. All adult patients undergoing their first BCHI over 6 years (April 1, 2017, to March 3, 2023). The Chronic Otitis Media Benefit Inventory (COMBI) score (postintervention) and the Glasgow Health Status Inventory (GHSI) (pre-and post-BCHI questionnaire). Improvements were seen across all COMBI domains. The mean total COMBI score was 46.3 (standard deviation = 5.3). Although expected significant improvements were seen in hearing and social domains, there were also notable gains in ear symptoms and reduced medical intervention post-BCHI. There was a statistically significant improvement in all GHSI scores post-BCHI (median total difference 67.1, p < 0.0001). This study reports very favorable outcomes for BCHI patients using two different PROMs: COMBI and GHSI. Although these PROMs complement each other, they also offer different perspectives on the same cohort of patients, with COMBI providing a unique insight into specific ear symptoms. This is the first reported study using this complement of PROMS in BCHI patients and offers further evidence for the wide-reaching improvements BCHI can have for patients.

To evaluate the quality of life (QoL) of patients with Chagas disease (CD) and the association between QoL domains and several clinical, socioeconomic and lifestyle characteristics of this population. Cross-sectional observational study conducted from March 2014 to March 2017 including a total of 361 outpatients followed at Evandro Chagas National Institute of Infectious Disease, Brazil. QoL was assessed using the Portuguese shorter version of the original WHO Quality of Life questionnaire (WHOQOL-BREF). Information about clinical CD presentation, presence of comorbidities, functional class, previous benznidazole treatment, socioeconomic profile and lifestyle was also obtained. Environment and physical domains presented the worst QoL scores, while the social relationship domain presented the highest score. Multivariate regression analysis demonstrated that variables independently associated with QoL were functional class, sex, clinical presentation of CD, sleep duration, schooling, physical activity level, smoking, income per capita and residents by domicile. The low socioeconomic status and the physical limitations imposed by the disease presented an important impact on the QoL reduction among CD patients, especially on environment and physical domains. Strategies to improve QoL among CD patients should be tailored and consider many different variables to maximise improvements not only of patients' physical but also of their mental health.

Objective Hearing loss is a growing public health issue that significantly impacts both health-related quality of life and working life. This study investigates how hearing rehabilitation with bone conduction hearing implants impacts health-related quality of life and working life in adults of working age with hearing impairment. Design This longitudinal study used data from Cochlear’s Implant Recipient Observational Study to assess hearing disabilities and job satisfaction in 18–65-year-old recipients of bone conduction hearing implants. Baseline data were collected pre-implantation and patients were followed-up at 12-months post-implantation. Study sample Patient demographics, Health Utilities Index Mark 3, the Speech Spatial and Qualities of Hearing Scale, and self-reported employment data are presented for a sample ranging from 30 to 43 patients, pre-implantation and at 12-months follow-up following implantation with a bone conduction hearing implant. Results Significant improvements in hearing and speech attribute, and overall health-related quality of life were observed between pre-and post-implantation. Overall hearing disability decreased post-implantation and job satisfaction improved. Conclusions Hearing rehabilitation using bone conduction hearing implants are shown to improve health-related quality of life, reduce hearing disability, and improve work performance and satisfaction. Results are representative of healthy and actively working users of bone conduction hearing implants.

Hearing impairment is a significant burden in the developing world. However, no suitable quality of life (QoL) measures exist for use in Nepal. We aimed to amend and translate the Glasgow Health Status Inventory (GHSI), assessing QoL at any given time, and the Glasgow Benefit Inventory (GBI), assessing change in QoL following intervention, into Nepali and to assess the impact of ear disease and effect of surgery on QoL. The GHSI and GBI were translated into Nepali and independently verified. The GHSI was administered by interview to patients before surgery, and the GBI was administered 6 months after surgery. The Mann-Whitney U-test was used for hypothesis testing. The GHSI was administered to 242 patients. In total, 205 had chronic suppurative otitis media (CSOM) without cholesteatoma and 37 had cholesteatoma. The mean GHSI score was 47.9. There was no significant difference in GHSI scores between patients with CSOM without cholesteatoma and those with cholesteatoma. The GBI was administered to 161 patients, 73 of whom had also been in the GHSI group. In total, 130 had CSOM without cholesteatoma, 31 had cholesteatoma. The mean GBI score was +38.4 with no significant difference between disease groups. Ear disease in Nepal is associated with reduced QoL, and surgical intervention is associated with improved QoL. There is no difference in QoL or benefit following surgery for CSOM between patients with or without cholesteatoma. There are few QoL measures suitable for the developing world. It is essential to invest in these measures to guide health interventions.

IntroductionModern medicine offers a wide spectrum of different hearing devices, and bone conduction implants can be found among them. ObjectiveThe presentation of the outcomes of the implantation of a new active bone conduction hearing implant – the Osia®, and its comparison with the well-known passive transcutaneous system – the Baha® Attract. MethodsEight adult patients with bilateral mixed hearing loss were randomly divided into two groups. Group 1 was implanted with the Osia®, and group 2 was implanted with the Baha® Attract. The details of the surgery were analyzed, along with the functional and audiological results. ResultsIn all the cases, the surgery was successful, and the healing uneventful. In both groups, it was observed that pure tone audiometry and speech audiometry in free field improved significantly after the implantation (mean gain in pure tone audiometry for the Osia group 42.8 dB SPL and for the Baha group 38.8 dB SPL). In the Osia group, the results after the surgery were much better than with the Baha® 5 Power processor on the Softband. The patients implanted with the Osia® evaluated the quality of their hearing as being superior to those implanted with the Baha® Attract. There was an evident improvement in the abbreviated profile of hearing aid benefit questionnaire and in the speech, spatial and qualities of hearing scale for both systems. In the abbreviated profile of hearing aid benefit, changes were more evident in the Osia group (in global score 49% vs. 37.2%). ConclusionImplantation of the Osia® is an effective treatment option for the patients with bilateral mixed hearing loss. The surgery is safe but more complex and time-consuming than the Baha® Attract implantation. The preliminary audiological results as well as the overall quality of life indicate that the Osia® is a better solution than the Baha® Attract. However, future studies should be carried out to make further observations in a larger group of patients, and with longer follow-up.

To evaluate changes in quality of life (QOL) and identify medical and socio-demographic predictors of QOL among breast cancer survivors 3 years after diagnosis. Between April 2002 and March 2004 2,232 women with breast cancer were recruited into the Shanghai Breast Cancer Survival Study, a population-based cohort study, approximately 6 months after cancer diagnosis. QOL was evaluated at 6 and 36 months post-diagnosis using the General Quality of Life Inventory. Multiple linear regression models were used to evaluate changes in QOL and their associations with socio-demographic and medical factors. In general, breast cancer patients showed significant improvement over time in the physical, psychological, and social well-being domains, as well as overall QOL. However, QOL scores in several facets did not improve or even deteriorated, including increased negative feelings, reduced social support and interpersonal relationships, and worsened financial situation and living environment. Age at diagnosis was inversely associated with QOL changes in physical and psychological well-being and overall QOL scores. Compared with those who were disease-free, patients with a recurrence of disease had significantly poorer QOL scores across all well-being domains and almost all facets. Patients who received radiotherapy experienced significant improvements in physical and social well-being and overall QOL. Mixed ER/PR status was associated with improved scores in physical and psychological well-being and overall QOL. Education, body mass index, Charlson comorbidity score, TNM stage, type of surgery, chemotherapy, and immunotherapy were only associated with changes in certain well-being domains and/or facets, but not overall QOL. Tamoxifen use was not associated with changes in QOL outcomes. Our study provides valuable information for developing strategies/interventions for improving the QOL of breast cancer patients.

The importance of quality of life issues in health care practice and research is steadily growing. This growing interest fits into the definition of health as proposed by the World Health Organization (WHO) in 1948 (1). The WHO defines health as 'a state of complete physical, mental and social well-being and not merely the absence of disease and infirmity'. The attention to health-related quality of life is reflected in the increase in the use of quality-of-life evaluation as a technique of clinical research since 1973, when only five articles listed 'quality of life' as a reference key word in the Medline data base; during the subsequent five-year periods there were 195, 273, 490, and 1252 such articles (2). Also in the field of allergy it has been recognized that allergic disease comprise more than the classical signs and symptoms being part of physical disorders such as allergic rhinitis, asthma and the atopic eczema/dermatitis syndrome (AEDS) (3). In the last decades an increasing effort has been made to understand the socioeconomic burden of atopic disease in terms of effects on health-related quality of life (HRQL) and healthcare costs. It has been acknowledged in several consensus reports that rhinitis and asthma are associated with impairments in the patients' functioning in day-to-day life at home, at work and at school 4-8). With the introduction of questionnaires designed to measure asthma- 9-11) and rhinitis-associated impairments of quality of life (12) it is clear that patients may be bothered by sleep disorders, emotional problems, impairment in activities and social functioning. Also, in general terms, patients with asthma (13) and allergic rhinitis (14) are impaired in their physical and mental functioning, including vitality and the perception of general health. From daily medical practice it can be easily understood that AEDS has a major impact on HRQL. In a way, the use of questionnaires focused on skin disease 15-17) formally confirms this association. Quality of life, QOL, has divergent meanings for different people. Also, HRQL may be considered as ill-defined. More agreement has been reached about the four domains of QOL which are considered to be important: 1) physical status and functional abilities; 2) psychological status and well-being; 3) social functioning; 4) economic and/or vocational status and factors ( 18 ). As the true quality of life value cannot be measured directly, researchers and clinicians have to resort to series of questions (items) to measure this construct indirectly. Combinations of items yield scores referring to physical, mental and social domains. An HRQL instrument must meet several criteria. It should address each component (symptom, condition) that is important to the patient. Attributes of an instrument are described in Table 1. It will be clear that the construction of quality of life questionnaires is a complex task, drawing from the fields of clinimetrics, psychometrics and clinical decision-making (2). Differences in approach, for instance item selection using factor analysis vs the impact method which select items that are most frequently perceived as important by patients -- yields different questionnaires (19). In general two types of instruments, generic and specific, have been used in allergy research. Generic questionnaires measure physical, psychological and social domains in all health conditions irrespective of the underlying disease. A frequently used generic instrument is the Medical Outcomes Survey Short Form 36 (SF-36) (20). The SF-36 was developed as part of the Medical Outcomes Study and analyzes health status using 36 questions to measure nine different health dimensions. It has been used to characterize patients with asthma. Bousquet (13) compared the FEV1 and a clinical score of asthma severity for 252 asthmatic patients. There was a significant positive correlation between all nine quality of life domains of the SF-36 and the clinical score of Aas. Eight of the nine domains also correlated with the FEV1. Also in perennial rhinitis there was a significant impairment in eight of nine QOL dimensions in patients compared with healthy subjects (14). Furthermore, the SF-36 is used to evaluate the effects of a nonsedating antihistamine on quality of life. In this study all of the nine quality of life dimensions improved significantly after one and six weeks of cetirizine treatment compared with placebo (21). Other generic instruments that have been used in allergy research are the Sickness Impact Profile (SIP) (22) and the Nottingham Health Profile (NHP) (23). The 136 items in 12 categories of the SIP describe activities of everyday living. This instrument has been used to evaluate the effect of salmeterol on asthma (24). Salmeterol led to significant improvements over salbutamol on virtually all clinical outcomes. Although all four quality of life instruments used in this study showed the same trend in favor of salmeterol, only the disease-specific Asthma Quality of Life Questionnaire (AQLQ) and the Rating Scale utilities showed significantly greater improvement on salmeterol than on salbutamol. In severe AEDS it was shown, using the SIP, that cyclosporin improves quality of life significantly (25). In particular, the SIP has been used for comparison with disease-specific instruments (24, 26-28). The NHP, the only generic instrument derived entirely from lay people, has been used to validate a disease-specific instrument for patients with dermatitis and psoriasis (29). In asthma the NHP was not able to capture clinical improvement by treatment with pulmonary steroids (30). The latter observations underline the disadvantage that the generic instruments miss depth and therefore may not be responsive enough to detect changes in general health states in spite of important changes in disease-related problems (26). The advantage of generic instruments, however, is that the burden of illness across different disorders and patient populations can be compared. In a comparison between asthma and epilepsy the major finding was that children with epilepsy had a relatively more compromised quality of life in the psychological, social, and school domains (31. In contrast, children with asthma had a more compromised quality of life in the physical domain. These findings suggested that attention simply to seizure control in the clinical setting will not address the full range of quality of life problems in children with epilepsy. Specific instruments have been designed by asking patients what kind of problems they experience from their disease. Both the frequency and the importance of impairments are measured by means of the questionnaires. These instruments have the advantage that they describe the disease-associated problems of the patients. As stated above, they seem to be more responsive to changes in HRQL than do the generic instruments. Several instruments for patients with asthma have been developed. The Asthma Quality of Life Questionnaire of Juniper is focused on symptoms, emotions, exposure to environmental stimuli, and activity limitation (32). Modifications of this questionnaire have been published recently (33, 34). When using HRQL outcome in clinical trials, the question arises whether a change in HRQL is of clinical importance. For the AQLQ, which uses a seven-point scale, the minimal important difference of quality of life score per item is considered to be very close to 0.5 (35). A change of 1.0 in the score represents a moderate change and a change in score of greater than 2.0 represents a large change in HRQL. The minimal important difference as described by Juniper is based upon patient opinions. Measures such as the standardized response mean or the effect size can be used to standardize changes. These measures are based solely upon the distribution of the observed data, in particular upon the variance (36). Recently, it has been shown that both the SF-36 and AQLQ were able to characterize a group of patients with moderate asthma very well, whereas the AQLQ domains were found to have the best discriminative properties (37. The Asthma Quality of Life Questionnaire of Marks captures breathlessness, physical restrictions, mood disturbance and concerns for health (38). St. George's Respiratory Questionnaire (11) is designed for patients with asthma and chronic obstructive pulmonary disorder COPD. It can be applied in both reversible and fixed airway obstruction. In contrast to other questionnaires, the Living with Asthma Questionnaire (10) does not include impairments experienced as a direct consequence of asthma symptomatology. Other instruments are presented in Table 2. The properties of the most frequently used questionnaire are described in Table 3. Specific instruments have been developed for children and caregivers (Table 2). In addition, questionnaires have been constructed for different age-groups of patients with rhinitis (12, 39-41). A simple practical questionnaire technique for routine clinical use, the Dermatology Life Quality Index (DLQI) has been introduced to characterize patients with skin disorders (15). This instrument has been used to compare patients with psoriasis and dermatitis (42). Also versions for children are available: the Children's Dermatology Life Quality Index (CDLQI) and the Infant's Dermatology Life Quality Index (IDLQI) (16). Other questionnaires are the Skindex (43) the Dermatology-Specific Quality of Life (DSQL) (17) and the patient-generated Dermatology Quality of Life Scales (DQOLS) (44). Recently, a questionnaire has been developed to measure HRQL in patients with allergy to insect stings. Subsequently, this instrument has been used in the evaluation of venom immunotherapy (45). It appeared that venom immunotherapy resulted in a statistically and clinically significant improvement in HRQL. Both in clinical practice and in research physicians and investigators rely on physiological and objective measures, whenever possible. However in asthma an increase in FEV1 or a decrease in PC20 histamine or methacholine may occur without any improvement experienced by the patient. Medical intervention may improve physiologic measures, whereas for instance side-effects of drugs or the cumbersome aspects of subcutaneous immunotherapy may unfavorably influence day-to-day life and compliance with treatment. It has been put forward that the classical outcome variables may only partially characterize the disease of the patient. From that point of view it has been advocated to measure HRQL along with the conventional clinical indices (46). In line with this reasoning is the weak association between classical asthma measures and the outcome of HRQL questionnaires. Comparison between de AQLQ of Marks with asthma symptoms and lung function variables revealed that a change in AQLQ score was weakly correlated with change in symptom score (r = 0.37, 95% CI 0.04–0.64) and change in BHR (r = 0.38, 95% CI 0.06–0.64). The association with change in peak flow variability was weak (r = 0.12, 95% CI 0.26–0.47) (27). Similar observations have been reported by others 47-50). An interesting study shows that the mere presence of respiratory symptoms or a (gradually) reduced lung function is insufficient reason for patients to seek medical help. Subjects are more likely to consult their general practitioner once their quality of everyday life is affected or they experience variability in lung function (51). Also, rhinitis related quality of life appears to be moderately correlated to the more classical outcome variables used in clinical trials, such as daily symptom scores and nasal hyperreactivity (52). Another argument to use quality of life instruments lies in the headstart with respect to the knowledge of their validation, reliability and responsiveness compared to the common symptom scores or visual analogue scores (VAS) scales used at clinical trials. In the field of nasal allergy, validation or standardization of symptom scores has rarely been the subject of research. In asthma, even quite recently introduced measures, such as the number of symptom-free days, merit more attention in terms of standardization and validation (53). Other reasons to assess quality of life are conceivable. Measurement of quality of life can also be useful for screening purposes or for evaluation of therapy. Quality of life may be a determinant of effectiveness or efficacy of treatment. Moreover, its assessment might be relevant to striving for optimal decision-making. As the perception of patients is clearly important in the management of disease and patient compliance (Fig. 1), measurement of this 'dimension' by HRQL questionnaires in clinical trials may be justified. The emphasis on quality of life has sometimes resulted in a routine inclusion of HRQL questionnaires in clinical trials. The inclusion of such an instrument is valuable only if the changes can be interpreted by clinicians and contributes to optimal medical decision-making. In an editorial, criticism has been directed to the routine inclusion of such instruments when the structure of the evaluation and its rationale appears ill-defined (54). A model representing the relationships between clinical aspects of therapy, HRQL and factors influencing HRQL (adapted from Cramer and Spilker (17)). Generally in clinical trials the effect of treatment or intervention on HRQL runs parallel with the effect on conventional medical outcome measures. However, in some studies differences can be found. In a study evaluating the combined effect of steroids and antihistamines no differences were demonstrated between patients treated with antihistamine and steroids vs steroids alone in terms of quality of life, whereas for some patient-rated symptoms the combination turned out to be superior (55). In a large multicenter study comparing budesonide and fluticasone it was found that both drugs were equally effective in suppressing symptoms (56), although budesonide had a better effect on general quality of life (57). This might indicate that patients perceive differences not captured by conventional symptom scores. The reverse situation, i.e. significant effects on classical outcomes (symptom scores, medication use, peak flow or FEV1) without important change in two generic and two specific HRQL measures has been described in a study on the effect of formoterol, a long-acting α2-agonist, in mild to moderate asthmatic patients (58). The latter discrepancies can be explained by a limited performance of HRQL measures in mild asthmatic patients. Alternatively, it is possible that the minor changes in symptom scores and lung function due to the intervention are not perceived by patients as relevant. Moreover, patients with a chronic condition may adapt themselves to their disease. The strength of HRQL questionnaires, that is the patient-centred approach, is also one of its weaknesses. Perceptions of quality of life experienced by persons may shift in time. It is easy to understand that a dramatic personal accident or a serious disease will not only cause deterioration in quality of life but will eventually also influence the patient's values and internal standards. For instance, in a study of quality of life after radiotherapy for laryngeal cancer, a temporary deterioration of physical functioning and symptoms was reported, mostly caused by side-effects of treatment. Despite physical deterioration, there was an improvement of emotional functioning and mood after treatment, probably as a result of psychological adaptation and coping processes (59). It is possible also that in less dramatic circumstances, disease and treatments will induce shifts in perception due to changes in the patient's values. Such subjective changes in patients' perception are known as response shift. Socioeconomic status is an additional important independent factor influencing HRQL. In a recent study with asthmatic patients it was shown that socioeconomic status attributes to HRQL. More importantly, in this study it was difficult to separate out the unique effects of socioeconomic status and race/ethnicity (60). Recently, a significant relationship between the mental health of children with asthma and family functioning has been shown (61). These findings suggest that the domains comprising the HRQL of children with asthma are related to both disease and non-disease factors. Psychological functioning influences the burden of a specific disease. A study designed to assess the effects of depressive symptoms on asthma patients' reports of functional status and health-related quality of life revealed that asthma patients with more depressive symptoms reported worse health-related quality of life than asthma patients with similar disease activity, but fewer depressive symptoms (62). Interestingly, these findings were seen not only in generic (SF-36) but also in specific (AQLQ) instruments. This means that a disease-specific instrument may be also influenced by phenomena such as fear and depression. Finally, patients may either intentionally or unconsciously mask their symptoms or trivialize their diseases. They may tend to ignore or discount those problems which they believe are unrelated to their illness. Others may tend to give socially desirable answers. Response shifts and illusory mental health (63) are not easily captured with HRQL instruments, but they will certainly influence the outcome of a clinical trial, when HRQL is chosen as the primary endpoint. In summary, one has to realize that the translation of clinical effects of treatment into perceived and reported changes in quality of life finds a place at the integration level of the patient and this is, in a way, a black box which is not easy to assess (Fig. 1). For these reasons it is strongly recommended to use HRQL outcome measures in parallel with conventional physiological outcome measures. Asthma, allergic rhinitis and AEDS often coexist. The question to what extent concomitant allergic disease affects quality of life has infrequently been addressed. In a recent study the SF-36 questionnaire from 850 subjects recruited in two French centers participating in the European Community Respiratory Health Survey was evaluated. Both asthma and allergic rhinitis were associated with impairment in quality of life. However, 78% of asthmatics also had allergic rhinitis. Subjects with allergic rhinitis but not asthma were more likely to report problems with social activities, difficulties with daily activities as a result of emotional problems, and low mental well-being than subjects with neither asthma nor rhinitis. Patients with both asthma and allergic rhinitis experienced more physical limitations than patients with allergic rhinitis alone, but no difference was found between these two groups for concepts related to social/mental health (64). In another study focusing on asthma, rhinitis and AEDS, comprising 325 subjects allergic to house dust mites, it was found that patients did show impaired quality of life compared to irrespective of the of the atopic Patients with the of asthma did out in terms of physical In addition, asthma symptoms with a visual had a major effect on social functioning, emotional functioning and disorders, in patients with AEDS, appeared to be associated with physical functioning, social functioning, mental health and general health It is not only concomitant atopic disease that has an impact on quality of life. such as and and nasal may patients with rhinitis and asthma. the SF-36 and a quality of life measure it has been shown that HRQL is impaired and that may improve quality of life for patients that is a other specific instruments such as the Index and the have been The impact of on social life in children during the four of life is not easily can be by use of a specific which measures the quality of life is a chronic disease of the respiratory which is frequently associated with respiratory compared the HRQL in patients with nasal with those of patients with perennial rhinitis and healthy It appeared that nasal impaired HRQL more than perennial allergic rhinitis The impairment of HRQL was greater when nasal was associated with asthma In addition, of nasal symptoms, and pulmonary function were after the evaluation in patients with nasal These demonstrated that nasal treatment either with nasal steroids or significantly improved both nasal symptoms and QOL without significant changes in pulmonary may a if the or is in one particular disease. A recent study the effects of on the of QOL measures an analysis of data from clinical trials with asthma, and The study suggest that conditions significantly and patients' scores on generic QOL measures and of treatment whereas their influence on disease-specific QOL scores and of treatment effect is although not These findings have significant practical for the of true treatment control of and the of QOL trials. The that atopic disease may have an effect on daily functioning has been by studies focused on school and in children with asthma may school and as as work by In a study it was shown that of children with recent symptoms of asthma, reported school absence for at one during the 12 compared with in children without respiratory absence of respiratory illness was reported for and use for respiratory problems for of the children with recent symptoms of asthma In another study reported in their activities and reported of work and school of asthma or nasal symptoms are not in patients with allergic rhinitis they may to problems during school either by direct or of sleep and allergic rhinitis may be associated with reduced to with will these problems, whereas treatment with nonsedating will only partially reverse the limitations in Recently, in a study out over in children with allergic perennial rhinitis and children with perennial rhinitis, it was shown that or the from on school on school and sleep In of the of a large it has been demonstrated that in asthma with increasing disease severity The of the effect of asthma on work the effect of work on asthma. The of asthma and of asthma is increasing It has been that of asthma can be to of asthma at work more on the of of underlying asthma than on the of possible asthma. It can be that patients with asthma may have a more severe impairment in quality of life of the between work and disease. In a study designed to address this question a statistically significant difference was seen in the scores of the AQLQ from a group of patients with asthma and a control group of subjects with asthma of The mean difference in the score was on a of limitation or of the to limitation or all the at the of the patient with asthma The difference between both groups was other more generic instruments focused on detect more showed that both asthma and rhinitis work with asthma are less likely to be at those rhinitis is a more determinant of work effectiveness In the allergic rhinitis in school days, and reduced activity per These data are derived from persons allergic rhinitis in with persons medical treatment. These data indicate that allergic rhinitis may have an important impact on and Patients are bothered by with performance and at and and may and only disease but also may influence work It has been that of treated their allergic rhinitis with antihistamines at for per Patients these antihistamines are more likely to The of include and With the antihistamines these problems have been significantly reduced studies have the for treatment of allergic rhinitis, asthma and associated In asthma in the for an A comparison of asthma in developed suggested an burden from to per of the asthma were to direct medical For the it has been that the when allergic was the primary were in The when allergic was a to other disorders such as asthma and was at The of allergic asthma and rhinitis and concerns about health care the increasing interest for only does the efficacy of treatment have to be but also its In these studies measures must be in to across patient populations and for different It is, however, difficult to the generic SF-36 or disease-specific HRQL scores into For this utilities such as the have been which measure the value that patients themselves place on their health some utilities measure the value that on health are the and Health An advantage of utilities is their to life associated with different medical can easily be into instruments are mostly A recent rhinitis specific the has been developed as a patient outcome for clinical trials and for studies comparing medical treatments for rhinitis The same group introduced an asthma specific the Asthma Index Also, disease-specific versions of the and have been developed for patients with asthma The interest in quality of life for patients with allergy that allergy is by a significant socioeconomic the introduction of HRQL outcome measures physicians were that patients cannot be by physiological measures. In a way, HRQL outcome measures of the from the with which clinicians are in their day-to-day The of these in the HRQL questionnaires it possible to include the patient in clinical trials and the in this field will improve medical decision-making and management of disease. of these outcome measures in the evaluation and management of patients be the However, HRQL questionnaires are in the of being in terms of and introduction of of instruments of QOL data is based on the that there are no measurement in the of is an technique for and which measurement into An important of is that it of whether a model fits the observed With this it has been shown that some changes in the of the SF-36 are when it is applied to evaluation of QOL for patients with or disease and with experienced criticism has been the of instruments and the to the measurement of quality of life It has been that attention has to be to better for of and of measures, these instruments will be for use in clinical practice and for use as primary in clinical trials Also, in the field of allergy the number of outcome measures is growing. For the and it will be difficult to select the of questionnaires. A a clinical is in of an disease-specific questionnaire with a whereas a at the level of health a generic instrument differences between subjects at a point in and utilities to assess of In not to patients with outcome measures research is to between In research to be focused on the selection and of a limited number of and instruments in to better understand the patient with allergy and better the of clinical trials. from the of Medical and for of the and

There exists a lacuna in the structured reporting of swallowing dysfunction and quality of life (QoL) outcome following major glossectomy. Prospective cohort study to assess the swallowing dysfunction and QoL following STG (subtotal glossectomy) or NTG (near total glossectomy) over a 6-month period using FEES and PAS scale, MDADI, and FACT-HN. Twenty-four patients were available for analysis. The pre- and post-adjuvant evaluation revealed a statistically significant improvement in the composite MDADI and FACT-HN scores. Subscale analysis of FACT-HN scores revealed maximum deficit in the head and neck cancer-specific score domain followed by functional domain and social well-being domain, with serial improvement noted in the post-adjuvant setting. This study showed serial improvement in terms of swallowing dysfunction although social and functional well-being domains related to QoL continued to reveal major deficits. Better outcomes were seen with preservation of bilateral base of tongue and mandible.

Complications of bone-conduction hearing implants (BCHI) implantation surgery.

For many years, the therapeutic approach for conductive and/or mixed hearing loss has consisted of middle ear surgery with replacement of defect ossicles, and if possible the application of a hearing aid. Advances in technology have led to the introduction of electronmagnetic active implantable devices such as the Vibrant Soundbridge (VSB). With its various coupling techniques for different pathophysiological situations in the middle ear, the VSB offers greater improvement in the hearing performance of affected persons. PubMed, OvidSP (MEDLINE), EMBASE (DIMDI), the National Institue for Health research (NIHR) Centre for Reviews and Dissemination (including the National Health Service Economic Evaluation Database, Database of Abstracts of Reviews of Effects, and Health Technology Assessment), and the Cochrane Library were searched to identify articles published between January 2006 and April 2014 that evaluated the safety and effectiveness of the VSB in comparison to no intervention, bone conduction hearing implants (BCHI), and middle ear surgery plus hearing aids for adults and children with conductive or mixed hearing loss. Study selection and data extraction was carried out by multiple reviewers. Study quality was assessed using the Oxford Centre for Evidence-Based Medicine levels of evidence (2011); and a checklist available from the Evidence Analysis Library, Academy of Nutrition and Diabetics. Thirty-six publications were identified: 19 on VSB outcomes in 294 individuals, 13 on BCHI outcomes in 666 individuals, and four on middle ear surgery plus hearing aid outcomes in 43 individuals. Two systematic reviews were also identified. Heterogeneous outcome measures made it difficult to summarize data. In general, the VSB proved to be safe and effective when compared to no intervention and BCHI, and provided more and consistent hearing gain compared to middle ear surgery plus conventional hearing aids. As demonstrated in the literature, the VSB as an active device offers an effective alternative for patients with various middle ear pathologies, particularly with mixed hearing loss and failed previous tympanoplasties when classical ossiculoplasty could not provide enough functional gain. This new strategy in hearing rehabilitation has led to an improved quality of hearing and life. Laryngoscope, 126:1451-1457, 2016.

Background: Chronic otitis media is a major public health burden that can result in a disabling hearing loss. Bone conduction hearing implants are an accepted form of hearing rehabilitation in these patients, but evidence supporting their usage typically comes from studies investigating mixed indications. The objective of our study was to examine how these devices impact health-related quality of life and hearing-disability in adult patients suffering from chronic otitis media. Methods: Health Utilities Index-mark III (n = 10) and Speech Spatial and Qualities of Hearing-49 data (n = 6) were extracted for adult patients with chronic otitis media from an international hearing implant registry. Data were compared at baseline and at 12-month post-implantation with a bone conduction hearing implant. Results: Patients demonstrated a clinically relevant mean utility gain of 0.145 following implantation and clinically relevant mean improvement in global speech spatial and qualities of hearing score following implantation. Conclusions: Bone conduction implantation was found to improve hearing and health-related quality of life and reduce hearing disability in a small cohort of patients with chronic otitis media. These data highlight the importance of providing appropriate hearing rehabilitation for individuals with chronic otitis media.

Background Breast cancer is the most frequent cancer among women all over the world. Breast cancer risk increases with age and about a third of female breast cancers are diagnosed in patients aged older than 70 years. Elderly breast cancer patients are affected by poorer quality of life (QoL) compared with younger patients. Aim The current study aimed to assess QoL of elderly women with breast cancer who received chemotherapy at Cancer Institute, Sohag Governorate. Research questions What is the QoL of breast cancer elderly women who received chemotherapy at Sohag Cancer Institute? Design Cross-sectional descriptive design was utilized. Sample Purposive sample of 100 elderly women with breast cancer, who completed all cycles of chemotherapy 1–3 months at least from the last dose of chemotherapy. Setting This study was conducted at the oncology building at outpatient clinics for cancer patients follow-up at Sohag Cancer Institute. Tools (1) Structured interviewing questionnaire for demographic and medical data. (2) QoL scale to assess QoL issues relevant to breast cancer patients (Algamdi and Hanneman, 2016). Results The results revealed that selected breast cancer elderly women aged from 60 to 80 years with mean 63.47±4.87 years. Seventy-two percent of them could not read and write, and 62% of them lived in rural areas. Seventy-eight percent suffered from chronic diseases. The mean of social well-being domain was 2.98±0.56, the mean of emotional well-being domain was 2.32±1.34, the mean of physical well-being domain was 1.79±1.15, and the mean of total Functional Assessment of Cancer Therapy – Breast was 2.24±0.31. More than half of the women had poor QoL, more than one-third of them had fair QoL, and a minority had good QoL. Conclusion The current study concluded that 60% of the selected breast cancer elderly women had poor QoL, whereas 38% had fair QoL and only 2% had good QoL. Also, it revealed that more than half of women had poor physical, functional well-being, and additional concerns and about half of them had good social well-being. Recommendations The current study recommends use of QoL scale in elderly women with breast cancer in oncology outpatient clinics in different cancer institutes and conduction of health education programs and further research works for improving QoL in elderly women with breast cancer.

Introduction: The lifestyle of quilombola communities has changed due to extra community influence, thus affecting their environmental and behavioral factors related to the Metabolic Syndrome (MS). However, little is known about the influence of MS on the Quality of Life (QoL) of quilombola residents. Objective: We aimed to study the association between MS and QoL in quilombola communities in northern Tocantins, Brazil.&#x0D; Methods: The QoL of 147 adults from five quilombola communities from Tocantins was assessed using the WHOQOL-BREF instrument. Blood pressure, abdominal perimeter, fasting blood glucose, triglycerides and HDL-cholesterol were measured, and the presence of MS was defined as the alteration of at least three of these clinical aspects. The association of the clinical components and the SM presence with the Quality of Life was evaluated by Student’s t-test for independent samples.&#x0D; Results: We observed that in the total population, an altered abdominal perimeter had an inverse association with both the Physical (15.2 vs. 14.0, p=0.002) and General QoL domains (14.4 vs. 14.0, p=0.045), and MS was inversely associated with the Physical domain (14.9 vs. 14.0, p=0.030). When stratified by sex, the altered abdominal perimeters in men were inversely associated with the Physical (16.5 vs. 14.4, p&lt;0.001), Environmental (14.0 vs. 12.6, p=0.020) and General domains (15.5 vs. 14.0, p&lt;0.001). MS had an inverse association with the Physical (15.8 vs. 14.4, p=0.026) and General domains (14.8 vs. 14.0 p= 0.042) in men. In women there was no association between any risk factor studied and QoL domain.&#x0D; Conclusions: The status of MS was negatively associated with the quality of life of the male population, highlighting the abdominal perimeter, which influences the Physical and General domains of QoL, but in the female population the MS does not interfere in the perception of QoL. Understanding the relationship between chronic diseases and QoL in quilombola communities is necessary to reduce health inequalities in historically vulnerable communities.&#x0D;

Tinnitus and its management in patients with vestibular schwannoma.

It is recognized that family (or friend) caregivers (FCGs) of patients with cancer undergo significant stress. Multiple past studies have shown that caregivers experience such negative effects as psychological distress, relationship disruptions, erosion of well-being, and even a higher incidence of cardiac diseases. Despite all this, FCGs are largely ignored by support services. For these reasons, a study was initiated to help provide evidence-based models to support FCGs of patients with lung cancer (Cancer. 2015;121:3737–3745). “Family caregivers are providing the majority of informal care for cancer patients in the community,” says Virginia Sun, RN, PhD, the current study's lead author and assistant professor in the department of population sciences at the City of Hope Comprehensive Cancer Center in Duarte, California. “There is an urgent need for interventions to support family caregivers in the caregiving role and their own physical, psychological, social, and spiritual needs. Our intervention can serve as an effective and replicable palliative care model for family caregivers of lung cancer patients.” Dr. Sun and her colleagues performed a 2-group prospective study at their institution. Between November 2009 and December 2010, FCGs were enrolled in the usual-care group. FCGs in the palliative care intervention arm were enrolled between July 2011 and August 2014. FCG quality of life (QOL) was obtained using a validated tool that measures QOL in the domains of physical, psychological, social, and spiritual well-being. Caregiver burden was assessed using a tool that measures caregiving impact on 3 aspects of burden: objective burden, subjective demand, and subjective stress. A caregiver skills preparedness scale was also employed. Patients’ QOL and symptoms were measured using the Functional Assessment of Cancer Therapy-Lung tool, which measures physical, social, emotional, and functional well-being. After the baseline assessment, follow-up questionnaires were administered to FCGs at 7 weeks and 12 weeks. Patients with non-small cell lung cancer of any stage were enrolled, and they identified a FCG who was also enrolled. A total of 157 FCGs in the usual-care group and 197 in the intervention group were included in the primary outcome analysis. Key Points In the intervention arm, a personalized palliative care plan was devised based on the results of the initial comprehensive QOL assessment. These patients and FCGs were also presented at weekly multidisciplinary care meetings at which recommendations were made concerning ways to support them. In addition, these FCGs received 4 educational sessions addressing QOL issues. Multivariate analysis of QOL and psychological distress indicated that FCGs in the intervention group had significantly improved QOL in the social well-being domain and significantly lower psychological distress compared with the usual-care group. In terms of spiritual well-being, FCGs in the usual-care group had significantly higher QOL compared with the intervention group. None of these results was found to differ by the patient's stage of disease. Differences were also noted between caregiver burden scores for the 2 FCG arms. The intervention group reported significantly fewer problems with objective burden or perceived disruption of their life. In comparison with the usual-care group, the intervention group also had significantly fewer FCGs with elevated subjective stress (13% vs 24%; P = .008). There were no associations found between the 2 groups with regard to subjective demand, defined as the extent to which the FCG perceives care responsibilities to be overly demanding. In addition, no significant differences were noted between groups with regard to caregiver skills preparedness. “This is an important study as it is the first that I know of to assess the impact of a palliative care support intervention on both the patient and their family,” says Diane Meier, MD, professor of geriatrics and palliative medicine at Mount Sinai Hospital in New York City, who was not involved in this study. “The findings show clear benefit of an added layer of palliative care support in terms of key caregiver outcomes.” Furthermore, the finding that spiritual QOL was significantly improved in the usual-care group compared with the intervention group may have indicated that this subject was not covered enough and that a future study may help to clarify how to provide beneficial interventions. The authors conclude that studies concerning the long-term effects of FCG interventions, as well as generalizing them to other cancer diagnoses and in community practices, are needed. “Currently, at the City of Hope, we have an ongoing American Cancer Society-funded research scholar grant that is testing the palliative care intervention for family caregivers who are poor and underserved,” says Dr. Sun. “We are targeting family caregivers of cancer patients diagnosed with gastrointestinal, gynecological, or genitourinary malignancies in this project.” “The intervention is structured, standardized, and potentially generalizable to other settings,” says Dr. Meier. “I don't see why this could not be done in a community setting with properly trained and designated staff. I am not aware of other comparable models being used in the community setting, but I think this is primarily due to scarce resources, not lack of need.”